Which type of calcium channel blocker is preferred for rate control in Afib?

Which type of calcium channel blocker is preferred for rate control in Afib?

• A. Dihydropyridine
• B. Non-dihydropyridine
• C. Both classes equally
• D. None of the above

Answer: (B)

Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, are preferred for rate control in atrial fibrillation (Afib) due to their ability to slow conduction through the atrioventricular (AV) node. This characteristic is crucial in managing the heart rate during Afib, as it helps to prevent excessive ventricular rates that can occur when the atria are fibrillating. By effectively interacting with the AV node, non-dihydropyridines can help restore a more controlled heart rhythm and improve symptoms associated with rapid heart rates. Dihydropyridine calcium channel blockers, on the other hand, primarily focus on vasodilation and do not significantly affect AV nodal conduction. Because they lack the same impact on heart rate control, they are not suitable for the management of patients with Afib where rate control is a key goal. Thus, the specific action of non-dihydropyridine calcium channel blockers makes them the preferred choice for this situation. The other options present choices that either do not specifically target the needed effects for rate control in Afib or suggest an equal efficacy that does not align with current clinical practices and guidelines.

Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, are preferred for rate control in atrial fibrillation (Afib) due to their ability to slow conduction through the atrioventricular (AV) node. This characteristic is crucial in managing the heart rate during Afib, as it helps to prevent excessive ventricular rates that can occur when the atria are fibrillating. By effectively interacting with the AV node, non-dihydropyridines can help restore a more controlled heart rhythm and improve symptoms associated with rapid heart rates.

Dihydropyridine calcium channel blockers, on the other hand, primarily focus on vasodilation and do not significantly affect AV nodal conduction. Because they lack the same impact on heart rate control, they are not suitable for the management of patients with Afib where rate control is a key goal. Thus, the specific action of non-dihydropyridine calcium channel blockers makes them the preferred choice for this situation.

The other options present choices that either do not specifically target the needed effects for rate control in Afib or suggest an equal efficacy that does not align with current clinical practices and guidelines.